Table 1 Patient characteristics
From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Number | Percentage | ||
|---|---|---|---|
Pathological complete response (pCR) versus residual disease (RD) | RD | 113 | 80.7 |
pCR | 24 | 17.1 | |
Unknown | 3 | - | |
Residual cancer burden | 0 | 24 | 22.6 |
I | 7 | 6.6 | |
II | 47 | 44.3 | |
III | 28 | 26.4 | |
Unknown | 34 | - | |
Estrogen receptor (ER) status | ER- | 62 | 44.3 |
ER+ | 78 | 55.7 | |
Progesterone receptor (PR) status | PR- | 82 | 58.6 |
PR+ | 58 | 41.4 | |
HER2 status | HER2- | 125 | 89.3 |
HER2+ | 15 | 10.7 | |
Grade | Grade 1–2 | 56 | 48.7 |
Grade 3 | 59 | 51.3 | |
Unknown | 25 | - | |
Nodal status and T stage | N0 | 41 | 29.3 |
N1 | 62 | 44.3 | |
N2 | 30 | 21.4 | |
N3 | 7 | 5.0 | |
T1 | 9 | 6.4 | |
T2 | 71 | 50.7 | |
T3 | 21 | 15.0 | |
T4 | 39 | 27.9 | |
Ethnicity | Asian | 3 | 2.1% |
Black | 13 | 9.3% | |
Hispanic | 50 | 35.7% | |
Caucasian | 74 | 52.9% | |
Systemic therapy | FAC/FEC | 63 | 45.0% |
TFAC/TFEC | 77 | 55.0% | |
Median age (minimum-maximum), years | 51 (28–73) | ||